CN115720520A - 用于预防和/或治疗哺乳动物疾病的组合物和方法 - Google Patents

用于预防和/或治疗哺乳动物疾病的组合物和方法 Download PDF

Info

Publication number
CN115720520A
CN115720520A CN202180042656.8A CN202180042656A CN115720520A CN 115720520 A CN115720520 A CN 115720520A CN 202180042656 A CN202180042656 A CN 202180042656A CN 115720520 A CN115720520 A CN 115720520A
Authority
CN
China
Prior art keywords
ksp37
protein
viral
subject
ksp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042656.8A
Other languages
English (en)
Chinese (zh)
Inventor
奥尔加 帕特丽夏 杰尔斯提拉 达 希尔瓦·史密斯 米歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biro Gene Co ltd
Original Assignee
Biro Gene Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biro Gene Co ltd filed Critical Biro Gene Co ltd
Publication of CN115720520A publication Critical patent/CN115720520A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180042656.8A 2020-07-09 2021-07-09 用于预防和/或治疗哺乳动物疾病的组合物和方法 Pending CN115720520A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ZA2020/04008 2020-07-09
ZA2020/03850 2020-07-09
ZA202003850 2020-07-09
ZA202004008 2020-07-09
PCT/IB2021/056179 WO2022009165A1 (en) 2020-07-09 2021-07-09 Compositions and methods useful for the prevention and/or treatment of disease in mammals

Publications (1)

Publication Number Publication Date
CN115720520A true CN115720520A (zh) 2023-02-28

Family

ID=79552952

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042656.8A Pending CN115720520A (zh) 2020-07-09 2021-07-09 用于预防和/或治疗哺乳动物疾病的组合物和方法

Country Status (16)

Country Link
US (1) US20240091310A1 (https=)
EP (1) EP4178604A4 (https=)
JP (1) JP2023533162A (https=)
KR (1) KR20230038230A (https=)
CN (1) CN115720520A (https=)
AU (1) AU2021304479A1 (https=)
BR (1) BR112022026874A2 (https=)
CA (1) CA3179965A1 (https=)
CL (1) CL2023000073A1 (https=)
CO (1) CO2022019251A2 (https=)
IL (1) IL299661A (https=)
MX (1) MX2023000113A (https=)
PE (1) PE20231554A1 (https=)
PH (1) PH12023550038A1 (https=)
WO (1) WO2022009165A1 (https=)
ZA (1) ZA202213371B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025215561A1 (en) * 2024-04-09 2025-10-16 Viro-Gen (Pty) Ltd Plasmid for expression of ksp37
WO2025221871A1 (en) * 2024-04-16 2025-10-23 The Trustees Of Columbia University In The City Of New York Expansion, propagation, and modulation of immune cell subsets by peptides
WO2025233868A1 (en) * 2024-05-07 2025-11-13 Viro-Gen (Pty) Ltd Compounds, compositions and methods for treating, reversing or preventing cancer
WO2025233869A1 (en) * 2024-05-07 2025-11-13 Viro-Gen (Pty) Ltd Compounds, compositions and methods for treating, reversing or preventing type 2 diabetes mellitus

Also Published As

Publication number Publication date
JP2023533162A (ja) 2023-08-02
EP4178604A4 (en) 2024-07-31
PH12023550038A1 (en) 2024-03-11
KR20230038230A (ko) 2023-03-17
WO2022009165A1 (en) 2022-01-13
IL299661A (en) 2023-03-01
BR112022026874A2 (pt) 2023-01-24
CA3179965A1 (en) 2022-01-13
AU2021304479A1 (en) 2023-01-19
PE20231554A1 (es) 2023-10-03
MX2023000113A (es) 2023-03-16
EP4178604A1 (en) 2023-05-17
ZA202213371B (en) 2023-11-29
CO2022019251A2 (es) 2023-03-27
US20240091310A1 (en) 2024-03-21
CL2023000073A1 (es) 2023-07-07

Similar Documents

Publication Publication Date Title
CN115720520A (zh) 用于预防和/或治疗哺乳动物疾病的组合物和方法
JP7162895B2 (ja) Ｈｉｖ予備免疫化および免疫療法
JP7260170B2 (ja) 事前の免疫化ステップのないｈｉｖ免疫療法
JP6890831B2 (ja) Ｈｉｖ予備免疫化および免疫療法
JP2019517503A (ja) 遺伝子編集戦略によるｈｉｖ−１のネガティブフィードバック調節
WO2021178571A1 (en) On demand expression of exogenous factors in lymphocytes to treat hiv
OA21071A (en) Compositions and methods useful for the prevention and/or treatment of disease in mammals.
WO2025064901A2 (en) Hiv vaccination and immunotherapy
WO2004065575A2 (en) Dna compositon and uses thereof
Lori Virostatics: A new frontier in the treatment of HIV/AIDS
Lederman Immune success and immune failure in HIV infection: implications for therapeutic intervention
Miller HYDROXYUREA: EIGHT YEARS'EXPERIENCE
Habibi Mechanisms of selective immunosuppressive effects of indoleamine 2, 3-dioxygenase and borrelidin
Montaner HAART-Mediated Immune Reconstitution as a Target for Therapy Management and Immunotherapy
Autran Therapeutic Immunization Against HIV
Clotet Treatment Interruptions Guided by CD4 Counts and Viral Load
Weiner Active Vaccine Immune Therapy for HIV-1
Silvestri Naturally Occurring Immunomodulation: Siv Infection in Sooty Mangabeys
Wainberg Does Impaired HIV Viral Fitness Result in Enhanced Durability of the Anti-HIV Immune Response?
Youle The Future of IL-2 in HIV
Gatell Immune-Based Therapies: Clinical Experience With Immunomodulators and Therapeutic Immunization
Kinloch The Quest Study, From a Clinician With Immunological Inclination
Franchini IL-7 and IL-15 as Vaccine Adjuvants in Macaque SIV Infection
Perno Immunological Effects of Novel Mutational Strategies for Viral Escape
Maserati Therapeutic Vaccination With A Gp120-Depleted Whole Killed Virus Vaccine Candidate (Remune) in Antiretroviral-Naive Hiv-Infected Patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination